Details of the Drug Reposition

General Information of This Drug (ID: DMHQKN6)

Drug Name
CART-19   DMHQKN6
Drug Type
CAR T Cell Therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 2 [1]
Acute lymphoblastic leukaemia DIS87TGM 2A85 Phase 2 [1]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 2 [2]
------------------------------------------------------------------------------------
4 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
leukaemia DISS7D1V 2A60-2B33 Phase 1 [3]
Follicular lymphoma DISVEUR6 2A80 Phase 1 [1]
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 1 [1]
B-cell lymphoma DISIH1YQ 2A86 Phase 1 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
2 ClinicalTrials.gov (NCT02030834) Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
3 ClinicalTrials.gov (NCT01626495) Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma